Multitargeted tyrosine kinase inhibitor stimulates expression of IL-6 and activates JAK2/STAT5 signaling in acute myelogenous leukemia cells To develop molecular targeted therapy for acute myelogenous leukemia (AML), it is important to verify the molecular mechanisms by which AML cells acquire drug resistance to the inhibitors of the receptor tyrosine kinases (RTKs), such as CD117 (c-KIT) and fms-like tyrosine kinase 3 (FLT3). To address this issue, we have established the RTK-resistant Kasumi-1 subline (designated as Kasumi-1R) by culturing Kasumi-1 cells prosurvival signaling. 2 Exposure of Kasumi-1R cells to sunitinib failed to inactivate janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) signaling, although c-KIT was effectively dephosphorylated in these cells (Figure 1b) , suggesting that c-KIT-independent activation of JAK2/STAT5 signaling might contribute to sunitinib resistance in Kasumi-1R cells. JAK2/STAT5 signaling is known to be activated by interleukin-6 (IL-6). In fact, Kasumi-1R cells aberrantly expressed a variety of inflammatory cytokines, including IL-6, compared with the parental Kasumi-1 cells (Figure 1c) . Further studies found that pre-incubation of Kasumi-1 cells with IL-6 (500 ng/ml, 24 h) blunted the ability of sunitinib to inhibit the proliferation of these cells (data not shown), confirming that aberrant expression of IL-6 contributed to sunitinib resistance of Kasumi-1 cells. We next explored whether exposure of Kasumi-1 cells to tyrosine kinase inhibitors, including sunitinib, would stimulate the expression of IL-6. Sunitinib and KRN383, with selectivity against FLT3, platelet-derived growth factor receptor and c-KIT, increased the levels of IL-6 by approximately fourfold (Figure 2a) . Imatinib also stimulated the expression of IL-6 in Kasumi-1 cells (Figure 2a) . The selective inhibitor of vascular endothelial growth factor receptor, PTK787/ZK222084, did not stimulate the expression of IL-6 (Figure 2a) . AG490, the inhibitor of JAK2, decreased the levels of IL-6 by 20% (Figure 2a) . In addition, sunitinib stimulated the expression of IL-6 in freshly isolated leukemia cells from AML patients (n ¼ 2), as well as in the peripheral blood mononuclear cells from healthy volunteers (n ¼ 3) (data not shown). Moreover, we found that administration of sunitinib (n ¼ 5, 20 mg/kg, 5 days) to C57BL/6 mice stimulated the expression of IL-6 in their spleen lymphocytes (Figure 2b ). We next attempted to verify the molecular mechanisms whereby sunitinib stimulated the expression of IL-6 in Kasumi-1R cells. The transcription factor, c-Jun, binds to the activator protein-1 site of the promoter region of IL-6 gene and intimately regulates its expression. 3 The nuclear levels of c-Jun in Kasumi-1R cells were significantly higher than those in Kasumi-1 cells (Figure 3a) . Chromatin immunoprecipitation assay found that an amount of c-Jun on the IL-6 promoter was greater in Kasumi-1R cells than those in Kasumi-1 cells (Figure 3b ). In addition, exposure of Kasumi-1 cells to sunitinib (100 nM, 48 h) prominently stimulated the binding of c-Jun on the IL-6 promoter (Figure 3b) .
It is noted that, tocilizumab (20 mg/ml), a humanized anti-IL-6 receptor antibody, or AG490 (5 mM) effectively blocked JAK2/STAT5 signaling (data not shown) and restored the sensitivity of Kasumi-1R cells to sunitinib (Figures 4a and b) , confirming the critical roles of IL-6/JAK2/ STAT5 axis in acquisition of drug-resistant character of Kasumi-1 cells.
Recent studies exploring the effects of the multitargeted tyrosine kinase inhibitor in AML patients harboring the activating mutation in FLT3 found that STAT5 was not efficiently dephosphorylated in some of the patients who did not respond to the inhibitor, although phosphorylation of FLT3 was effectively inhibited in these patients. 4 The multitargeted tyrosine kinase inhibitor could induce the expression of IL-6, leading to the activation of JAK2/STAT5 signaling in these patients. Inhibition of this prosurvival signaling by tocilizumab or the specific inhibitor of JAK2 might improve the clinical outcome of these patients.
BCR/ABL kinase-positive CD34 þ stem/progenitor cells from chronic myeloid leukemia (CML) display elevated levels of DNA double-strand breaks (DSBs) induced by reactive oxygen species (ROS) and various genotoxic agents, including g-radiation.
1 To survive, CML cells repair these numerous DSBs, which generate chromosomal aberrations because BCR/ABL kinase affects the fidelity of repair mechanisms. 1 Thus, CML cells can accumulate additional chromosomal aberrations during the course of disease (ROS dependent) and also in cells surviving bone marrow transplantation (genotoxic agent dependent). The latter statement is supported by the reports that CD34 þ CML stem and progenitor cells are resistant to genotoxic agents. 2 Our earlier studies showed that BCR/ABL kinase interacts with RAD51 resulting in its phosphorylation on Y315, which stimulates repair of DNA lesions by the homologous recombination repair (HRR). 3 HRR is responsible for the repair of about 43% of DSBs in BCR/ABL-transformed cells. 4 RAD51 protein promotes homology search and strand invasion during HRR, which uses an undamaged copy of broken DNA as a template for the repair process. 5 Homologous recombination repair events are also regulated by RAD51 paralogs, RAD51B, RAD51C, RAD51D, XRCC2 and XRCC3. 6 The paralogs can form various complexes in human cells displaying different functions during HRR. For example, RAD51C-XRCC3 and RAD51D-XRCC2 catalyze homologous pairing, and RAD51B-RAD51C is likely required for the assembly of the RAD51-ssDNA nucleoprotein filament. The formation of RAD51 foci after DNA damage is dependent on the paralogs and suggests the existence of functional interactions between these proteins. Cells defective in any of the RAD51 paralogs are sensitive to DNA-damaging agents and to g-radiation.
We have shown previously that in addition to RAD51, expression of RAD51 paralogs may be de-regulated in CMLblast crisis cells, implicating their role in malignant disease progression. 3 For example, RAD51B was upregulated, whereas XRCC3 was downregulated.
Using pull-down assay we found that BCR/ABL interacts with glutathione S-transferase (GST)-RAD51B, but not GST-XRCC3 in a kinase-independent manner (Figure 1a) . This interaction
